Grifols acquires Biotest, expanding catalog of plasma donation centers
Catalan pharma-chemical company Grifols (Nasdaq: GRFS) announced on Wednesday that it had acquired 100% of Biotest Pharmaceuticals for $286 million, expanding its US presence by almost 1,000 employees.
The deal, which had been stalled until American antitrust bodies could give their approval, will see Grifols acquire Biotest's corporate headquarters in Florida, as well as 22 operative plasma banks in the USA with a further two currently under construction.
The US Federal Trade Commission placed several restrictions on the deal, including ordering Grifols to divest three of its 24 new centers and prohibiting the company from acquiring any ownership stake in ADMA Biologics (Nasdaq: ADMA), a company to which Biotest had previously sold assets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze